U.S. Patent and Trademark Office: U.S. DEPARMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

[					-n	
PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)					Docket Number (Optional)	
FY 2009 {Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).}				133087.09001(101	133087.09001(101026-1PUS)	
Application Number 10/550,760				Filed September 27	Filed September 27, 2005	
For Use Of ATII Antagonist For The Treatment Or Prevention Of Metabolic Syndrome						
Art Unit 1628				Examiner Timothy P	Examiner Timothy P. Thomas	
This is a request under the provisions of 37 CFR 1.136(a) to extend the penod for filing a reply in the above identified application.						
The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):						
			Fee	Small Entity Fee		
		One month (37 CFR 1.17(a)(1))	\$130	\$65	\$	
		Two months (37 CFR 1.17(a)(2))	\$490	\$245	\$	
		Three months (37 CFR 1.17(a)(3))	\$1110	\$555	\$	
		Four months (37 CFR 1.17(a)(4))	\$1730	\$865	\$	
		Five months (37 CFR 1.17(a)(5))	\$2350	\$1175	\$	
	Applica	ant claims small entity status. See 37 CFR 1.27.				
A check in the amount of the fee is enclosed.  Payment by credit card. Form PTO-2038 is attached.						
	The Di	actor has already been authorized to charge fees in this application to a Deposit Account.				
	The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.  I am the applicant/inventor.						
assignee of record of the entire interest, See 37 CFR 3.71, Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96).						
attorney or agent of record. Registration Number 38534						
attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34						
/Paul K. Legaard, Reg.#38534/ 6 December 2010						
	Signature				Date	
	Paul K. Legaard, Ph.D.			610.640.7859	610.640.7859	
Typed or printed name				Teleph	Telephone Number	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.						
☐ Total of one forms are submitted.						

This ordiscion of information is sequently by 37 CFR 1.13(a). The information is required to obtain or retain is benefit by the public which is to file lead by the USFR 0.15(crosses) as explicated in confidenting in pages required by \$1.3 CB. 2.5 as \$1.2 CFB. 3.1 cB. at 1.4. This reduction retinated in the induses to complete, including gathering preparing, and submitting the completed application form to the USFRO. Time will vary depending upon the individual case. Any comments on the manual of time kye transplants to complete in Sorm analysis upon the levels to for manual formation of the USFRO. The second of the preparation of the preparation of the USFRO. The second of the preparation of the USFRO. The preparation of the USFRO. The preparation of the USFRO. The USFRO. The USFRO. The USFRO. The USFRO. The preparation of the USFRO. T

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursuant to 5 U.S.C. 552a/m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 2994 and 2905. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application prusuant to 35 U.S.C. 12(b) or issuance of a patent pursuant to 35 U.S.C. 12(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.